On January 23, 2020, at 6.30 am, Neo-Science booth at beyond zero Nairobi County medical safari opened its doors to clients seeking NIPT and hereditary cancer screening. A team of ten service providers (doctors, nurses, phlebotomists, and volunteers) was assigned various responsibilities; client’s triage, pretest counseling, phlebotomy, and posttest counseling.
Thirty-ﬁve pregnant women visited our booth for NIPT services. Using the screening criteria outlined above, 14 women met selection criteria for NIPT testing and 10 ml venous blood sample was collected and shipped to the testing laboratory. Two samples were rejected because of insufﬁcient quantity (resampling recommended) and one was not tested because the woman her pregnancy was already full term and she was due for delivery in two weeks’ time from date of the camp.
The average gestation period was 27.9 weeks (range 24-38weeks). For the 11 pregnant women whose results are available, all have a low risk for Trisomy 18, 21 and 13. Clients were contacted, and results shared with their health care providers.
During the last decade, developments in the science of genetics and enormous advances in genetic technologies have altered our capability to understand diseases, make diagnoses and provide eﬀective treatments. Transforming the world of prenatal testing, the advent of new DNA-based non-invasive prenatal testing (NIPT) has introduced a highly accurate screening strategy for fetal aneuploidy The NIFTY® test (Non-Invasive Fetal TrisomY test) was the ﬁrst NIPT to enter clinical testing in 2010 and has been validated by a study on nearly 147,000 pregnancies. As of 2019, over 4,000,000 NIFTY® tests have been carried out worldwide.
“NIFTY® offers screening for some of the most common trisomies present at birth, including trisomy 21 (Down’s Syndrome), trisomy 18 (Edward’s Syndrome) and trisomy 13 (Patau Syndrome). NIFTY® also provides testing options for sex chromosomal aneuploidies, chromosomal deletions, and gender.”
Leave a reply